Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally
According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...
STAT2h
Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
Citius Pharmaceuticals’ Lymphir and Keytruda Combo Shows Promising Clinical Outcomes, Earning a Buy Rating
Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...